English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/57176
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Affinity maturation of antibodies assisted by in silico modelling

AuthorsBarderas, Rodrigo ; Desmet, Johan; Timmerman, Peter; Meloen, Rob H.; Casal, J. Ignacio
KeywordsAntibody engineering
Gastrinin
Vitro affinity maturation
Pancreatic cancer
Issue Date1-Jul-2008
PublisherNational Academy of Sciences (U.S.)
CitationProceedings of the National Academy of Sciences, 105(26):9029-9034(2008)
AbstractRational engineering methods can be applied with reasonable success to optimize physicochemical characteristics of proteins, in particular, antibodies. Here, we describe a combined CDR3 walking randomization and rational design-based approach to enhance the affinity of the human anti-gastrin TA4 scFv. The application of this methodology to TA4 scFv, displaying only a weak overall affinity for gastrin17 (K D = 6 μM), resulted in a set of nine affinity-matured scFv variants with near-nanomolar affinity (K D = 13.2 nM for scFv TA4.112). First, CDR-H3 and CDR-L3 randomization resulted in three scFvs with an overall affinity improvement of 15- to 35-fold over the parental. Then, the modeling of two scFv constructs selected from the previous step (TA4.11 and TA4.13) was followed by a combination of manual and molecular dynamics-based docking of gastrin17 into the respective binding sites, analysis of apparent packing defects, and selection of residues for mutagenesis through phage display. Nine scFv mutants were obtained from the second maturation step. A final 454-fold improvement in affinity compared with TA4 was obtained. These scFvs showed an enhanced potency to inhibit gastrin-induced proliferation in Colo 320 WT and BxPc3 tumoral cells. In conclusion, we propose a structure-based rational method to accelerate the development of affinity-matured antibody constructs with enhanced potential for therapeutic use
Description6 páginas, 2 figuras, 4 tablas -- PAGS nros. 9029-9034
Publisher version (URL)http://dx.doi.org/10.1073/pnas.0801221105
URIhttp://hdl.handle.net/10261/57176
DOI10.1073/pnas.0801221105
E-ISSN1091-6490
Appears in Collections:(CIB) Artículos
Files in This Item:
File Description SizeFormat 
restringido.pdf21,67 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.